What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Avelumab demonstrates a clear clinical advantage over chemotherapy, showing significant improvements in overall survival (OS) and progression-free survival (PFS) in the JAVELIN trial. The median OS was reported at 20 months, and the median PFS was 4.1 months, indicating a substantial therapeutic impact. However, the evidence is based on a single-arm trial, which limits the robustness of the findings.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for avelumab are within the acceptable range for Healthcare resources, with a base-case ICER of £17,947 per QALY gained. This suggests that avelumab is clearly cost-effective under common thresholds, supporting its use in the Healthcare.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee noted that avelumab offers benefits such as fewer side effects and a positive impact on quality of life compared to chemotherapy. While specific HRQoL data were not extensively detailed, the qualitative evidence from patient groups suggests moderate improvements in well-being.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Avelumab has a very good safety profile, with mostly mild to moderate adverse events reported. The committee concluded that the treatment is tolerable, with rare serious events, indicating a favorable safety profile compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The evidence includes an indirect comparison of avelumab with chemotherapy, but the committee noted concerns regarding the methodological robustness of the naive comparison. While the ERG preferred an adjusted analysis, the lack of direct head-to-head trials limits the strength of the comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in JAVELIN part B is broadly representative of the intended patient population, although it included a higher proportion of younger patients and those with better ECOG scores. The committee concluded that these differences do not significantly undermine the generalizability of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Avelumab can be integrated into existing treatment pathways with minor adjustments. The committee noted that it offers an alternative to chemotherapy, which is currently the standard treatment, indicating a manageable integration into clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of avelumab is manageable, with the potential for cost savings due to its effectiveness compared to chemotherapy. The committee’s analysis suggests that the resource implications are justifiable given the treatment’s benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from the JAVELIN trial, which, while robust, is a single-arm study. The committee acknowledged some limitations in the data, particularly regarding the maturity of the OS and PFS data, but overall considered the evidence acceptable.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the long-term outcomes and the maturity of the data, the context of high unmet need and the treatment’s life-extending potential for patients with metastatic Merkel cell carcinoma mitigates some of these concerns.
